Cardiomyocytes are another important site of MR expression, and antagonists such as spironolactone and epelerone are believed to mainly displace GCs bound to the MR in this cell type and thereby improve the outcome of patients suffering from heart diseases [8]. This evidence concerns the gene NR3C2 and heart disorder.